Pfizer Other Non-Cash Items 2010-2025 | PFE
Pfizer annual/quarterly other non-cash items history and growth rate from 2010 to 2025. Other non-cash items can be defined as miscellaneous non-cash adjustments to Net income.
- Pfizer other non-cash items for the quarter ending March 31, 2025 were $734M, a 69.74% decline year-over-year.
- Pfizer other non-cash items for the twelve months ending March 31, 2025 were $-1.016B, a 122.49% decline year-over-year.
- Pfizer annual other non-cash items for 2024 were $0.734B, a 69.74% decline from 2023.
- Pfizer annual other non-cash items for 2023 were $2.426B, a 255.02% decline from 2022.
- Pfizer annual other non-cash items for 2022 were $-1.565B, a 78.97% decline from 2021.
Pfizer Annual Other Non-Cash Items
(Millions of US $) |
| 2024 |
$734 |
| 2023 |
$2,426 |
| 2022 |
$-1,565 |
| 2021 |
$-7,440 |
| 2020 |
$836 |
| 2019 |
$-5,321 |
| 2018 |
$-1,178 |
| 2017 |
$-12,158 |
| 2016 |
$3,091 |
| 2015 |
$1,805 |
| 2014 |
$754 |
| 2013 |
$-7,420 |
| 2012 |
$-3,140 |
| 2011 |
$-1,368 |
| 2010 |
$5,129 |
| 2009 |
$-8,800 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$130.024B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
